Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Ikuo Hirano; Marc E. Rothenberg; Sandra Zhang; Claudia De Oliveira; Christina M. Charriez; Karin S. Coyne; Elizabeth Dansie Bacci; Evan S. Dellon

doi:10.14309/ajg.0000000000002094

Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Ikuo Hirano^*, Marc E. Rothenberg, Sandra Zhang, Claudia De Oliveira, Christina M. Charriez, Karin S. Coyne, Elizabeth Dansie Bacci, Evan S. Dellon

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

Original language	English (US)
Pages (from-to)	744-747
Number of pages	4
Journal	American Journal of Gastroenterology
Volume	118
Issue number	4
DOIs	https://doi.org/10.14309/ajg.0000000000002094
State	Published - Apr 1 2023

Funding

Financial support: This study was supported by Bristol Myers Squibb. Writing and editorial assistance were provided by Claire Jarvis, PhD, and John Simmons, MD, of Peloton Advantage, an OPEN Health company, funded by Bristol Myers Squibb.

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.14309/ajg.0000000000002094

Cite this

@article{f0c3d1afa62e4736b1b3a6c98b7dfbba,

title = "Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis",

abstract = "INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.",

author = "Ikuo Hirano and Rothenberg, {Marc E.} and Sandra Zhang and {De Oliveira}, Claudia and Charriez, {Christina M.} and Coyne, {Karin S.} and Bacci, {Elizabeth Dansie} and Dellon, {Evan S.}",

year = "2023",

month = apr,

day = "1",

doi = "10.14309/ajg.0000000000002094",

language = "English (US)",

volume = "118",

pages = "744--747",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

AU - Hirano, Ikuo

AU - Rothenberg, Marc E.

AU - Zhang, Sandra

AU - De Oliveira, Claudia

AU - Charriez, Christina M.

AU - Coyne, Karin S.

AU - Bacci, Elizabeth Dansie

AU - Dellon, Evan S.

PY - 2023/4/1

Y1 - 2023/4/1

N2 - INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

AB - INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

UR - http://www.scopus.com/inward/record.url?scp=85151312438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151312438&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000002094

DO - 10.14309/ajg.0000000000002094

M3 - Article

C2 - 36647838

AN - SCOPUS:85151312438

SN - 0002-9270

VL - 118

SP - 744

EP - 747

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 4

ER -

Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this